Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Biotechnology

Healthcare
$53.36 +1.69%

+$1.19 today

Market cap
$174.70M
Beta
1.13
P/E (TTM)
-194.1
EPS (TTM)
-$0.37
52W Low $6.96High $97.97

Volume 0.03M

Average 0.04M

SLGL Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Sol-Gel Technologies Ltd.NASDAQ: SLGL

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 154.8% from a year ago

Total equity stood at $51.41M at the end of Q1 FY2026, up 154.8% from a year earlier and up 125.4% from the prior quarter. Over 3 fiscal years it compounded at -18.5% a year.

Context

  • Total equity amounted to 87.8% of total assets at the end of Q1 FY2026, up 13.3 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +154.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.41M+125.4% QoQ
Last fiscal yearDec 2025
$22.81M-20.9% YoY
Year agoMar 2025
$20.17M+154.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+154.8%——
1 year-20.9%——
3-year CAGR-18.5%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
22.81M USD
Year-over-year change
-20.9%
4-year CAGR
-20.0%

Total Equity vs competitors

How SLGL compares with its peers on the latest reported figures

  • SLGL's Mar 2026 total equity of $51.41M is the 5th highest of the 10 companies compared; the peer median is $48.97M.
  • Its year-over-year change of +154.8% is the 2nd highest of 10, against a peer median of -35.8%.
  • Total equity amounts to 87.8% of total assets for SLGL, versus a peer median of 81.5%.
SLGL Competitors Peer median
Total Equity for SLGL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ORMPOramed Pharmaceuticals Inc.Mar 2026$238.28M +70.3%+9.7%88.6%
OVIDOvid Therapeutics Inc.Mar 2026$198.27M +234.5%-0.4%87.9%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$182.68M -38.2%-20.7%72.2%
PLRXPliant Therapeutics, Inc.Mar 2026$165.17M -35.8%-16.7%81.5%
SLGLSol-Gel Technologies Ltd.Mar 2026$51.41M +154.8%-18.5%87.8%
COYACoya Therapeutics, Inc.Mar 2026$48.97M +46.8%—91.9%
MGNXMacroGenics, Inc.Mar 2026$21.2M -73.2%-26.8%9.7%
TLSATiziana Life Sciences LtdDec 2025$52K -98.7%-86.1%0.5%
OKYOOKYO Pharma LimitedSep 2025-$3.42M +52.7%—73.5%
CLNNClene Inc.Mar 2026-$18.81M -278.2%—86.8%
Peer median (excluding SLGL) $48.97M-35.8%-18.7%81.5%

Competitors are the stored peer set for SLGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents20.09M12.45M7.51M19.49M11.03M
Short-term Investments23.16M21.18M30.48M4.44M12.97M
Net Receivables13.07M7.92M377K3.6M1.97M
Inventory00000
Other Current Assets002.79M3.77M1M
Total Current Assets57.11M43.06M41.17M31.3M26.97M
Property, Plant & Equipment (Net)2.55M1.54M2.16M1.63M1.17M
Goodwill00000
Intangible Assets00000
Long-term Investments8.7M1.29M1.28M2.32M1.32M
Tax Assets00000
Other Non-current Assets830K749K681K608K455K
Total Non-current Assets12.08M3.57M4.12M4.55M2.95M
Total Assets69.19M46.63M45.29M35.85M29.92M
Account Payables766K251K154K1.27M735K
Short-term Debt0000495K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00004.49M
Total Current Liabilities11.69M3.33M4.52M5.29M6.17M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.09M1.03M915K833K439K
Total Non-current Liabilities1.9M1.09M2.12M1.71M935K
Total Liabilities13.6M4.42M6.64M7M7.11M
Common Stock638K638K774K774K774K
Retained Earnings(178.14M)(193.07M)(220.3M)(230.88M)(237.01M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity55.59M42.21M38.64M28.85M22.81M
Total Debt1.59M772K1.65M1.31M991K
Net Debt(18.49M)(11.68M)(5.86M)(18.18M)(10.04M)

Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Intrinsic Alpha fair value

Locked

Current Price

$53.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.